UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 11, 2019
Supernus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
| | | | |
| Delaware | 001-35518 | 20-2590184 | |
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | |
| | |
| 1550 East Gude Drive | Rockville | MD | 20850 | |
| (Address of Principal Executive Offices) | | (Zip Code) | |
Registrant’s telephone number, including area code: (301) 838-2500
Not Applicable
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Exchange Act
|
| | |
| Title of each class | Trading Symbol | Name of each exchange on which registered |
| Common Stock, $0.001 par value per share | SUPN | The Nasdaq Global Market |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On November 11, 2019, Supernus Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it has submitted a New Drug Application to the U.S. Food and Drug Administration for SPN-812 for the treatment of patients with attention deficit hyperactivity disorder. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
On November 12, 2019, the Company issued a press release announcing that the Company’s management will present a Company overview and Company update as well as host investor meetings at the Stifel 2019 Healthcare Conference in New York, NY on November 19, 2019 and at the Jefferies 2019 London Healthcare Conference in London, U.K. on November 21, 2019. A copy of this press release is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit
The following document is furnished as an Exhibit pursuant to Item 8.01 hereof:
Exhibit 99.1 — Press Release Dated November 11, 2019.
Exhibit 99.2 — Press Release Dated November 12, 2019.
Exhibit 104 — The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
EXHIBIT INDEX
|
| | | | |
| Number | | Description | | |
| 99.1 | | | | Attached |
| | | | | |
| 99.2 | | | | Attached |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | |
| | SUPERNUS PHARMACEUTICALS, INC. |
| | |
| DATED: November 12, 2019 | By: | /s/ Gregory S. Patrick |
| | | Gregory S. Patrick |
| | | Senior Vice-President and Chief Financial Officer |
